

Rounds with the Investigators: National Research Leaders Provide Their Perspectives on the Management of Actual Patients with Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The results of the Phase II TREAT trial demonstrated that the combination of cisplatin and vinorelbine was better tolerated than cisplatin and pemetrexed for patients with early-stage NSCLC.
 - a. True
 - b. False
2. The TASTE trial is comparing adjuvant cisplatin/pemetrexed to customized adjuvant treatment based on EGFR and ERCC1 status for patients with nonsquamous NSCLC.
 - a. True
 - b. False
3. The PARAMOUNT trial demonstrated a statistically significant benefit in _____ for patients with advanced nonsquamous NSCLC who received maintenance pemetrexed compared to placebo.
 - a. Overall survival
 - b. Progression-free survival
 - c. Neither of the above
 - d. Both a and b
4. The National Lung Screening Trial reported a 20% relative reduction in mortality from lung cancer with low-dose CT screening.
 - a. True
 - b. False
5. In a study of afatinib with cetuximab for patients with NSCLC and disease progression on erlotinib or gefitinib, investigators reported confirmed responses in _____.
 - a. T790M mutation-positive disease
 - b. T790M mutation-negative disease
 - c. Both of the above
 - d. None of the above
6. The PointBreak study is comparing the ECOG-E4599 regimen (paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab) to which of the following?
 - a. Paclitaxel/carboplatin/bevacizumab → maintenance paclitaxel/bevacizumab
 - b. Pemetrexed/carboplatin/bevacizumab → maintenance bevacizumab
 - c. Pemetrexed/carboplatin/bevacizumab → maintenance pemetrexed/bevacizumab
7. The administration of *nab* paclitaxel does not require steroid premedication.
 - a. True
 - b. False
8. The Phase III MARQUEE trial is evaluating erlotinib with tivantinib for patients with _____ locally advanced or metastatic NSCLC.
 - a. Previously treated
 - b. Previously untreated
9. Patients with NSCLC and ROS1 rearrangements are highly unlikely to respond to crizotinib.
 - a. True
 - b. False
10. Results published by Zhu and colleagues in *The Journal of the American Medical Association* indicated that the addition of bevacizumab to carboplatin/paclitaxel was not associated with more favorable survival rates among older patients with advanced NSCLC.
 - a. True
 - b. False